These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 39419964)

  • 1. Therapeutic targeting of differentiation-state dependent metabolic vulnerabilities in diffuse midline glioma.
    Mbah NE; Myers AL; Sajjakulnukit P; Chung C; Thompson JK; Hong HS; Giza H; Dang D; Nwosu ZC; Shan M; Sweha SR; Maydan DD; Chen B; Zhang L; Magnuson B; Zhu Z; Radyk M; Lavoie B; Yadav VN; Koo I; Patterson AD; Wahl DR; Franchi L; Agnihotri S; Koschmann CJ; Venneti S; Lyssiotis CA
    Nat Commun; 2024 Oct; 15(1):8983. PubMed ID: 39419964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas.
    Koncar RF; Dey BR; Stanton AJ; Agrawal N; Wassell ML; McCarl LH; Locke AL; Sanders L; Morozova-Vaske O; Myers MI; Hamilton RL; Carcaboso AM; Kohanbash G; Hu B; Amankulor NM; Felker J; Kambhampati M; Nazarian J; Becher OJ; James CD; Hashizume R; Broniscer A; Pollack IF; Agnihotri S
    Cancer Res; 2019 Aug; 79(16):4026-4041. PubMed ID: 31201162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening.
    Lin GL; Wilson KM; Ceribelli M; Stanton BZ; Woo PJ; Kreimer S; Qin EY; Zhang X; Lennon J; Nagaraja S; Morris PJ; Quezada M; Gillespie SM; Duveau DY; Michalowski AM; Shinn P; Guha R; Ferrer M; Klumpp-Thomas C; Michael S; McKnight C; Minhas P; Itkin Z; Raabe EH; Chen L; Ghanem R; Geraghty AC; Ni L; Andreasson KI; Vitanza NA; Warren KE; Thomas CJ; Monje M
    Sci Transl Med; 2019 Nov; 11(519):. PubMed ID: 31748226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas.
    Ehteda A; Khan A; Rajakumar G; Vanniasinghe AS; Gopalakrishnan A; Liu J; Tsoli M; Ziegler DS
    Mol Cancer Ther; 2023 Dec; 22(12):1413-1421. PubMed ID: 37683275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
    Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
    Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALK2 inhibitors display beneficial effects in preclinical models of
    Carvalho D; Taylor KR; Olaciregui NG; Molinari V; Clarke M; Mackay A; Ruddle R; Henley A; Valenti M; Hayes A; Brandon AH; Eccles SA; Raynaud F; Boudhar A; Monje M; Popov S; Moore AS; Mora J; Cruz O; Vinci M; Brennan PE; Bullock AN; Carcaboso AM; Jones C
    Commun Biol; 2019; 2():156. PubMed ID: 31098401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma.
    Nagaraja S; Vitanza NA; Woo PJ; Taylor KR; Liu F; Zhang L; Li M; Meng W; Ponnuswami A; Sun W; Ma J; Hulleman E; Swigut T; Wysocka J; Tang Y; Monje M
    Cancer Cell; 2017 May; 31(5):635-652.e6. PubMed ID: 28434841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma.
    Lee S; Kambhampati M; Yadavilli S; Gordish-Dressman H; Santi M; Cruz CR; Packer RJ; Almira-Suarez MI; Hwang EI; Nazarian J
    J Neuropathol Exp Neurol; 2019 May; 78(5):380-388. PubMed ID: 30990879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.
    Xin DE; Liao Y; Rao R; Ogurek S; Sengupta S; Xin M; Bayat AE; Seibel WL; Graham RT; Koschmann C; Lu QR
    Neuro Oncol; 2024 Apr; 26(4):735-748. PubMed ID: 38011799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant.
    de Billy E; Pellegrino M; Orlando D; Pericoli G; Ferretti R; Businaro P; Ajmone-Cat MA; Rossi S; Petrilli LL; Maestro N; Diomedi-Camassei F; Pezzullo M; De Stefanis C; Bencivenga P; Palma A; Rota R; Del Bufalo F; Massimi L; Weber G; Jones C; Carai A; Caruso S; De Angelis B; Caruana I; Quintarelli C; Mastronuzzi A; Locatelli F; Vinci M
    Neuro Oncol; 2022 Jul; 24(7):1150-1163. PubMed ID: 34964902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.
    Duchatel RJ; Jackson ER; Parackal SG; Kiltschewskij D; Findlay IJ; Mannan A; Staudt DE; Thomas BC; Germon ZP; Laternser S; Kearney PS; Jamaluddin MFB; Douglas AM; Beitaki T; McEwen HP; Persson ML; Hocke EA; Jain V; Aksu M; Manning EE; Murray HC; Verrills NM; Sun CX; Daniel P; Vilain RE; Skerrett-Byrne DA; Nixon B; Hua S; de Bock CE; Colino-Sanguino Y; Valdes-Mora F; Tsoli M; Ziegler DS; Cairns MJ; Raabe EH; Vitanza NA; Hulleman E; Phoenix TN; Koschmann C; Alvaro F; Dayas CV; Tinkle CL; Wheeler H; Whittle JR; Eisenstat DD; Firestein R; Mueller S; Valvi S; Hansford JR; Ashley DM; Gregory SG; Kilburn LB; Nazarian J; Cain JE; Dun MD
    J Clin Invest; 2024 Feb; 134(6):. PubMed ID: 38319732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chorioallantoic membrane (CAM) assay to study treatment effects in diffuse intrinsic pontine glioma.
    Power EA; Fernandez-Torres J; Zhang L; Yaun R; Lucien F; Daniels DJ
    PLoS One; 2022; 17(2):e0263822. PubMed ID: 35157705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma.
    Meel MH; de Gooijer MC; Metselaar DS; Sewing ACP; Zwaan K; Waranecki P; Breur M; Buil LCM; Lagerweij T; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso Á; Bugiani M; Phoenix TN; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
    Clin Cancer Res; 2020 Jul; 26(13):3319-3332. PubMed ID: 32165429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience.
    Mueller T; Laternser S; Guerreiro Stücklin AS; Gerber NU; Mourabit S; Rizo M; Rushing EJ; Kottke R; Grotzer M; Krayenbühl N; Nazarian J; Mueller S
    Eur J Cancer; 2023 Jan; 178():171-179. PubMed ID: 36455411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parsing the effect of co-culture with brain organoids on Diffuse Intrinsic Pontine Glioma (DIPG) using quantitative proteomics.
    Prior VG; Maksour S; Miellet S; Hulme AJ; Chen Y; Mirzaei M; Wu Y; Dottori M; O'Neill GM
    Int J Biochem Cell Biol; 2024 Sep; 174():106617. PubMed ID: 39009182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
    Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
    J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
    Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
    Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design considerations of an IL13Rα2 antibody-drug conjugate for diffuse intrinsic pontine glioma.
    Lian X; Kats D; Rasmussen S; Martin LR; Karki A; Keller C; Berlow NE
    Acta Neuropathol Commun; 2021 May; 9(1):88. PubMed ID: 34001278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG.
    Balakrishnan I; Danis E; Pierce A; Madhavan K; Wang D; Dahl N; Sanford B; Birks DK; Davidson N; Metselaar DS; Meel MH; Lemma R; Donson A; Vijmasi T; Katagi H; Sola I; Fosmire S; Alimova I; Steiner J; Gilani A; Hulleman E; Serkova NJ; Hashizume R; Hawkins C; Carcaboso AM; Gupta N; Monje M; Jabado N; Jones K; Foreman N; Green A; Vibhakar R; Venkataraman S
    Cell Rep; 2020 Oct; 33(3):108286. PubMed ID: 33086074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo.
    Brown EJ; Balaguer-Lluna L; Cribbs AP; Philpott M; Campo L; Browne M; Wong JF; Oppermann U; Carcaboso ÁM; Bullock AN; Farnie G
    Sci Rep; 2024 Jan; 14(1):328. PubMed ID: 38172189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.